stable disease


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

stable disease

in oncology, less than 25% increase or less than 50% decrease in the size of all tumors.
Farlex Partner Medical Dictionary © Farlex 2012

stable disease

Oncology A state in which a CA has been treated and clinical signs of disease do not appear to ↑ or ↓ in extent or severity. See Remission.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

stable disease

In oncology, cancer that neither responds to treatment nor worsens significantly during treatment.
See also: disease
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Long-lasting stable disease ([greater than or equal to] 6 months) was noted in 6 (33.3%) patients including 2 patients who received second-line therapy.
It is also encouraging to see Phase I patients with poor prognosis experience long periods of stable disease after single therapy with CYC202.
"Patients with responding or stable disease had an estimated 90% 5-year overall survival," Dr.
In addition, previous Phase II studies, conducted in Europe on 125 patients with advanced MDS, demonstrated positive results: Of 121 evaluable patients, a response rate of 49 percent was observed, and an additional sixteen percent of the patients experienced stable disease. The average duration of remission was 9 months with a median survival rate of 22 months.
This is advised for confirming the diagnosis among patients with early-stage, stable disease. Such tests should be used periodically to track disease progression.
Of the nine mCRC patients, one neoadjuvant patient experienced a partial response according to RECIST 1.1 criteria and a total of six patients experienced stable disease at month three, including two neoadjuvant and four relapsed/refractory mCRC patients.
M2 PHARMA-November 22, 2017-DelMar VAL-083 Study Results in 40% of Recurrent GBM Patients Achieving Stable Disease
In September 2017, the company presented clinical data at the European Society for Medical Oncology (ESMO) Congress, showing that two of the 15 lung cancer patients under its Phase 2 trial continue to demonstrate stable disease after five years with monthly subcutaneous injections.
The mean undertreated tumor volume was 0.5 cc in patients with disease progression and 0.03 cc in those with stable disease. Larger tumor volumes and total treatment volumes correlated with worse cranial nerve function.
Patients with unstable disease returned in 8 weeks; those with stable disease returned in 15 weeks.